# US 2022/0033807 A1 · Method for capturing rna in situ higher-order structures and interactions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033807 A1
- Document ID: US20220033807A1
- Status: Published application
- Kind: A1
- Application number: 17/297,414
- Filed: 2019-07-05
- Published: 2022-02-03
- Earliest claimed: 2019-05-09
- Assignees: Institute of Biophysics, Chinese Academy of Sciences
- Applicants: Institute of Biophysics, Chinese Academy of Sciences
- Inventors: Yuanchao XUE; Zhaokui CAI; Changchang CAO
- Web page: https://patentgrep.com/patent/US20220033807A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12N 15/1065: {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- C12Q 1/6869: Methods for sequencing
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention discloses a method for capturing an RNA in situ higher-order structure and interaction. The method includes: fixing protein-mediated RNA-RNA interaction in cell or tissue; performing membrane permeabilization while keeping the cell intact; degrading free RNA; labeling the 3′ end of the RNA with pCp-biotin and performing proximal ligation in situ; purifying the chimeric RNA containing the pCp-biotin after the cell is digested; constructing the strand-specific library; and performing high-throughput sequencing. In the present invention, under the condition of not destroying the cell structure and keeping the integrity of cell, treat the intracellular RNA in situ, and capture RNA intra- and intermolecular interactions in a physiological state; the 3′ end of the RNA is labeled with the pCp-biotin, and in situ ligation is performed under non-denaturing conditions, thereby greatly improving the labeling efficiency and reducing intermolecular specific ligation; and the chimeric RNA labeled with C-biotin is enriched by C1 magnetic beads, so that the fraction of effective sequencing data is increased, and the sequencing cost is reduced.

## Claims

### Claim 1

A method for capturing an RNA higher-order structure in situ and/or verifying in situ RNA-RNA interaction, comprising the following steps:
(1) treating cell or tissue sample to fix protein-mediated RNA-RNA proximal interaction;
(2) performing membrane permeabilization while keeping the cell intact;
(3) degrading free RNAs that are not protected by protein;
(4) labeling the 3′ end of RNA protected by the protein with a “pCp-Marker 1” and performing proximal ligation in situ;
(5) purifying the chimeric RNA containing the “C-marker 1” after cells are digested; and constructing strand-specific library;
(6) performing high-throughput sequencing.

### Claim 2 (depends on 1)

The method according to claim 1, wherein in the step (1), treating cell or tissue sample is to perform formaldehyde cross-linking on the cell or tissue sample.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the step (1) is performed according to a method comprising the following steps:
(a1) placing the cell or tissue sample in formaldehyde solution at room temperature for 10 minutes.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the formaldehyde solution is 1% (v/v) formaldehyde solution.

### Claim 5 (depends on 3)

The method according to claim 3, wherein after the step (a1), the method further comprises the following step (a2):
(a2) adding glycine solution into the cell or tissue sample treated in the step (a1), and incubating for 10 minutes.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the glycine solution is a glycine solution with a concentration of 0.125 mol/L.

### Claim 7 (depends on 1)

The method according to claim 1, wherein in the step (2), the permeabilization solution used during the membrane permeabilization is a Permeabilization buffer; and the solvent of the Permeabilization solution is 10 mM Tris-HCl buffer with pH 7.5, and the solute and concentration are as follows: 10 mM of NaCl, 0.5% (v/v) NP-40, 0.3% (v/v) Triton X-100, 0.1% (v/v) Tween 20, 1×protease inhibitors and 2 U/ml of SUPERase.In™ RNase Inhibitor.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the step (2) is performed according to a method comprising the following steps:
(b1) placing the cell or tissue sample treated in the step (1) in the Permeabilization buffer at 0° C.-4° C. for 15 minutes.

### Claim 9 (depends on 8)

The method according to claim 8, wherein after the step (b1), the method further comprises the following step (b2):
(b2) washing the cell or tissue sample treated in the step (b1) with 1×PNK solution, wherein the solvent of the 1×PNK solution is 50 mM of Tris-HCl buffer with pH 7.4, and the solute and concentration are as follows: 10 mM of MgCl2, 0.1 mg/ml of BSA, and 0.2% (v/v) NP-40.

### Claim 10 (depends on 1)

The method according to claim 1, wherein in the step (3), the MNase is used for achieving the “degrading free RNAs that are not protected by protein”.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the step (4) can be performed according to a method comprising the following steps:
(d1) hydroxylating the 3′ end of the RNA protected by protein;
(d2) labeling the 3′ end of RNA as “Cp-Marker 1”;
(d3) converting the phosphate group in “Cp-Marker 1” at the 3′ end of the RNA into hydroxyl group;
(d4) phosphorylating the 5′ end of the RNA;
(d5) performing proximal ligation in situ.

### Claim 12 (depends on 11)

The method according to claim 11, wherein in the step (d1), by treating the sample treated in the step (3) with alkaline phosphatase, the 3′ end of the RNA protected by the protein can be hydroxylated.

### Claim 13 (depends on 11)

The method according to claim 11, wherein in the step (d2), by adding the “Cp-Marker 1” into the sample treated in the step (d1) to perform a ligation reaction, the 3′ end of the RNA is labeled as the “Cp-Marker 1”.

### Claim 14 (depends on 11)

The method according to claim 11, wherein in the step (d3), treating the sample treated in the step (d2) with the alkaline phosphatase to convert the phosphate group in the “Cp-Marker 1” at the 3′ end of the RNA into the hydroxyl group.

### Claim 15 (depends on 11)

The method according to claim 11, wherein in the step (d4), treating the sample treated in the step (d3) with T4 PNK enzyme to phosphorylate the 5′ end of the RNA.

### Claim 16 (depends on 11)

The method according to claim 11, wherein in the step (d5), by adding the T4 RNA ligase into the sample treated in the step (d4), the proximal ligation is performed in situ.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the step (5) is performed according to a method comprising the following steps:
(e1) using proteinase K to digest the cell;
(e2) extracting total RNA, and performing fragmentation treatment;
(e3) enriching the chimeric RNA labeled with “C-marker 1” by using magnetic beads on which the marker 2 is fixed; and the marker 2 can specifically bind to the marker 1;
(e4) constructing strand-specific library.

### Claim 18 (depends on 1)

The method according to claim 1, wherein in the method, the maximum starting amount of the cells is 1×107 cells.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the cell is animal cell, and the tissue is animal tissue.

### Claim 20 (depends on 1)

A library construction method, comprising the step (1) to the step (5) of the method according to claim 1.

### Claim 21 (depends on 20)

The library constructed by using the method of claim 20 for capturing an RNA higher-order structure in situ and/or identifying in situ RNA-RNA interaction.

### Claim 22 (depends on 1)

An application of the method according to claim 1 for identifying lncRNA targets in living cells.

### Claim 23

An application of pCp-biotin for identifying RNA-RNA proximal interactions.

### Claim 24

An application of pCp-biotin in RNA proximal ligation in situ.

### Claim 25

An application of pCp-biotin in chimeric RNA enrichment.

### Claim 26 (depends on 7)

An application of the detergent, which is the Permeabilization buffer in claim 7.

### Claim 27 (depends on 26)

An auxiliary use of the detergent described in claim 26 in the membrane permeabilization of cells.

### Claim 28

An application of the MNase, the alkaline phosphatase and/or the T4 polynucleotide kinase in the in situ ligation of RNA.
